GABA type-A (GABA-A) receptors containing the α2 subunit (Gabra2) are expressed in most brain regions and are 33 critical in modulating inhibitory synaptic function. Genetic variation at the GABRA2 locus has been implicated in epilepsy, 34 affective and psychiatric disorders, alcoholism and drug abuse. Gabra2 expression varies as a function of genotype and is 35 modulated by sequence variants in several brain structures and populations, including F2 crosses originating from 36 C57BL/6J (B6J) and the BXD recombinant inbred family derived from B6J and DBA/2J. Here we demonstrate a global 37 reduction of Gabra2 brain mRNA and protein in the B6J strain relative to other inbred strains, and identify and validate 38 the causal mutation in B6J. The mutation is a single base pair intronic deletion located adjacent to a splice acceptor site 39 that only occurs in the B6J reference genome. The deletion became fixed in B6J between 1976 and 1991 and is now 40 pervasive in many engineered lines, BXD strains generated after 1991, the Collaborative Cross, and the majority of 41 consomic lines. Repair of the deletion using CRISPR-Cas9 mediated gene editing on a B6J genetic background completely 42 restored brain levels of Gabra2 mRNA and protein. Comparison of transcript expression in hippocampus, cortex, and 43 striatum between B6J and repaired genotypes revealed alterations in GABA-A receptor subunit expression, especially in 44 striatum. These results suggest that naturally occurring variation in GABRA2 levels between B6J and other substrains or 45 inbred strains may also explain strain differences in anxiety-like or alcohol and drug response traits related to striatal 46 function. Characterization of the B6J private mutation in the Gabra2 gene is of critical importance to molecular genetic 47 studies in neurobiological research as this strain is widely used to generate genetically engineered mice and murine genetic 48 populations, and is the most widely utilized strain for evaluation of anxiety-like, depression-like, pain, epilepsy, and drug 49
Introduction

51
GABA-A receptors are pentameric ligand gated chloride channels responsible for fast inhibitory 52 neurotransmission. The sequence, structure, and chromosomal location of receptors and their cognate subunits are highly 53 conserved among mammals (Olsen and Sieghart, 2009 ). Receptors are typically composed of two α, two β, and a γ or δ 54 subunit with the most common receptor subtypes containing α1 or α2 subunits. Subunit composition can alter receptor 55 pharmacology and localization (Sieghart, 1995) . Receptors containing the α2 subunit (Gabra2) are abundantly expressed 56 in mouse hippocampus, frontal cortex, amygdala, dorsal and ventral striatum, and hypothalamus-brain regions 57 important for motivation, reward, anxiety, depression, and fear. Over 500 common human variants have been identified 58 at the GABRA2 locus, including numerous intronic variants, a handful localized to the UTRs, and one synonymous variant 59 in exon 4. Genetic variation at this locus has been linked to alcohol dependence (Covault et al., 2004; Edenberg et al., Consortium on Complex Epilepsies. Electronic address, 2014), and impulsivity and insula cortex activity during reward or 65 loss anticipation (Villafuerte et al., 2013) . Furthermore, interactions between early life stress and GABRA2 polymorphisms 66 may influence vulnerability to addiction (Enoch, 2008; Dick et al., 2009; Enoch et al., 2010) . However, the impact of these 67 variants on expression, isoform usage, or function of GABRA2 mRNA or protein is unclear (Myers et al., 2007; Heinzen et 68 al., 2008; Gibbs et al., 2010; Liu et al., 2010; Kim et al., 2014; Lieberman et al., 2015) . 69
Preclinical models can be useful in dissecting enigmatic relationships between human behavior and genetic 70 variation. Genetically engineered mouse models in which Gabra2 expression or sensitivity to modulation has been altered 71 (knock-out and knock-in) suggest a role for GABA-A receptors containing the α2 subunit in depression (Vollenweider et 72 al., 2011) , alcohol intake and behavioral response to alcohol (Boehm et al., 2004; Blednov et al., 2011; Liu et al., 2011; 73 Blednov et al., 2013) , anxiety (Dixon et al., 2008) , and cocaine-conditioned reinforcement and behavioral sensitization 74 (Morris et al., 2008; Dixon et al., 2010b) . Genetic deletion of Gabra2 is also associated with a decrease in miniature 75 inhibitory postsynaptic current in the nucleus accumbens core (Dixon et al., 2010b ), suggesting an important role of 76
Gabra2 in modulating inhibitory signaling in this region. However, no studies to date have characterized naturally 77 occurring variants segregating among murine populations that could alter Gabra2 levels or function, and provide insight 78 into the role of human variants. 79
In this study, we leverage naturally occurring variation in murine genetic populations of varying complexity in 80 order to better understand the role of Gabra2 variants on gene function. We previously profiled gene expression data 81 from multiple mouse strains and crosses, including nearly isogenic C57BL/6 substrains and the well-characterized BXD 82 family of strains derived from a cross between B6J and DBA/2J (D2) inbred mice, to characterize genetic variation in Gabra2 83 expression (Mulligan et al., 2012) . Here we identify the source of this variation as a spontaneous intronic deletion in B6J 84 that underlies variation in Gabra2 mRNA and protein expression across diverse murine populations that incorporate B6J 85 as a progenitor strain. We have quantified molecular and behavioral consequences of the private mutation in B6J by 86 CRISPR-Cas9 genome editing. This work demonstrates the functionality of often ignored non-coding variants in the mouse 87 genome and characterizes the downstream consequences of Gabra2 variation on molecular traits. 88
Methods
90
Mice. C57BL/6J-Tyr<c-2J> mice were purchased from Jackson Laboratories and C57BL/6NCrl mice were purchased from 91
Charles River Laboratories at 8 weeks of age and allowed to acclimate for 9 days at UTHSC before tissue collection. 92 C57BL/6J, DBA/2J, C57BL/6NJ, C57BL/6JEiJ, and C57BL/6ByJ are maintained in-house up to generation 6 at UTHSC from 93 Jackson Laboratory stock. BXD mice are maintained at UTHSC. The B6-Gabra2 em1Geh / J CRISPR repair line was generated at 94 the University of Pittsburgh (as described below) and is maintained as a heterozygous breeding colony by the Mulligan 95 laboratory at UTHSC. All mice were housed in same-sex cages, allowed ad-lib access to food and water and maintained 96 on a 12h/12h light/dark cycle in a climate-controlled facility. Only adult mice (between 70 and 200 days of age) were 97 included in the study. All animal care and handling procedures were approved by the UTHSC and the University of 98 Hippocampus Exon (Feb09) RMA, and GN732 GTEXv5 Human Brain Hippocampus RefSeq (Sep15) RPKM log2 106 (Consortium, 2013) . In addition to references provided, additional information on these data sets can also be found at 107
GeneNetwork.org. 108
Tissue collection. The cortex, hippocampus and striatum (dorsal and ventral) were dissected from up to three males and 109 three females for each strain (effective strain n = 5 or 6). At time of tissue harvest, purchased mice were ~9 weeks and 110 in-house strains were ~8 weeks of age. Tissue was immediately frozen in liquid nitrogen and stored at -80 °C until 111 further use. Additional peripheral tissue, including the liver and spleen, was also dissected from each strain and stored at 112 -80 °C until further use. Whole brains from wild-type Gabra2 B6J/B6J , homozygous Gabra2 KI/KI and heterozygous Gabra2 KI/-113 mice were dissected and placed in glass scintillation vials, which were subsequently kept at -80°C. To prepare for sub 114 dissection of whole frozen brains, the brains were kept at -20 °C at least 30 min prior to dissection. Whole brains were 115 placed dorsal side down into a brain matrix, with two coronal cuts being made by single edge razor blades to obtain 116 striatal tissue. The first cut was made rostral and proximal to the optic chiasm (bregma -3.0), and the second cut was 117 made two millimeters forward from the first cut (bregma +2.0). Hippocampus and cortex were then sub-dissected from 118 the brain tissue remaining caudal to the first razor blade cut. Gabra2 homozygous knockout brains were kindly provided 119 by Y. Blednov at the University of Texas at Austin. These mice were maintained on a mixed C57BL6Jx129/SvEv 120 background at the University of Sussex and were backcrossed twice to B6J at the University of Texas. Tissue was flash 121 frozen in liquid nitrogen, and immediately (within 1-2 days) shipped on dry ice to UTHSC where cortex, hippocampus 122 and striatum were dissected and stored at -80 °C until further use. 123 qPCR to validate mRNA levels. Five biological replicates were used for each strain and consisted of both males and 124 females (two to three of each sex). RNA was isolated from brain tissue using the RNeasy Lipid Tissue kit (Qiagen), with 125 cDNA then being generated from 1 μg of RNA utilizing the First Strand Reverse Transcriptase kit (Roche). Quantitative 126 PCR was utilized to assess target gene expression using the KAPA SYBR Fast QPCR Master Mix, probes from Roche's 127 Universal ProbeLibrary, custom primers from Integrated DNA Technologies (IDT), and a Roche Light Cycler 480 II. 128
Universal probes and custom primers were selected and designed, respectively, using the Universal Probe Library 129 (www.universalprobelibrary.com; Roche Diagnostics). For Gabra2 (NM_008066.3) we used Universal Probe #103 and 130 the following primers: Left-ACAAAAAGAGGATGGGCTTG and Right-TCATGACGGAGCCTTTCTCT. Cyclophilin D 131 (NM_026352.3) was selected as the endogenous control gene for all tissues (Schmittgen and Livak, 2008) . Data was 132 analyzed using the ΔΔCt method as described in (Livak and Schmittgen, 2001) , with C57BL/6J selected as the reference 133 or calibrator strain to calculate fold-change expression. For gene expression in the CRISPR mice, the coefficient of 134 variation was quantified using the ΔCt method. All statistical tests were conducted in R using R Studio (RStudio: 135
Integrated Development for R. RStudio, Inc., Boston, MA). One-way ANOVA was performed for comparing more than 136 two independent samples, with Tukey's HSD post-hoc test subsequently applied to assess pairwise significance between 137
genotypes. 138
Validation of genomic variants. Variants that were polymorphic between the B6J reference genome and B6NJ and D2 139 were identified using 100X coverage of the D2 genome available at http://ucscbrowser.genenetwork.org/ (Wang et al., 140 2016 ) and the Welcome Trust Sanger Institute ( sequenced genomes available for 36 inbred mouse strains, including the 141 B6NJ substrain, at http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl). Initially we identified two high 142 quality indels located on Chr 5 at 71,014,638 bp (deletion) and 71,031,384 bp (rs225241970, deletion), and a highly 143 conserved intergenic SNP located at 70,931,531 bp (all coordinates given based on the mm10 assembly). Genomic DNA 144 was extracted from B6J, D2, B6NJ, B6EiJ, B6ByJ, BXD29, and BXD40 using the DNeasy Blood & Tissue Kit (Qiagen) from 145 frozen liver or spleen tissue. Variants were genotyped using primers designed against the reference genome using the 146 Core using the ABI Prism 3130 Genetic Analyzer system. The only variant that could not be confirmed was the indel 154 rs225241970 located on Chr5 at 71,031,384 bp as none of the seven strains tested, including B6J, were polymorphic at 155 this position. This genomic region includes a microsatellite repeat (CA)n that may have led to sequencing errors in the 156 reference genome. 157
Traditional western analysis. Lysates were prepared from frozen tissue and protein concentration was determined using 158 a Nanodrop2000 Spectrophotometer (ThermoScientific). 50 μg of total protein was loaded and separated on a 7.5% SDS-159 PAGE gel. Proteins were transferred using the Bio-Rad TurboTransfer system and blocked for 30 minutes at room 160 temperature. For chemiluminesence western blots, blots were incubated in primary antibody for GABRA2 (1:500 rabbit 161 polyclonal, PhosphoSolutions, Cat #822-GA2CL) overnight at 4°C. Blots were washed 3x5mins with blocking buffer and 162 incubated with horseradish-peroxidase conjugated antibody for 1h at room temperature. Blots were developed using 163 the Super Signal West Pico Chemiluminescent Substrate kit (ThermoScientific #34080) on a BioRad ChemiDoc imaging 164 system. Blots were then incubated in a stripping solution (Restore Western Blot Stripping Buffer, ThermoScientific 165 #21059) for 8 minutes, re-probed overnight at 4C with a GAPDH antibody (1:5000, mouse monoclonal, Fitzgerald, Cat 166 #10R-G109A), and developed again the following day. For fluorescent western blots, blots were incubated with both 167 primary antibodies together overnight at 4C, followed by anti-rabbit and anti-mouse fluorescent-conjugated antibodies. 168
Visualization was performed using an Odyssey image scanner. Blot intensities across all blots were quantified using 169
ImageJ. Original blots can be found in SFigs 1 and 2. 170 Collected data was searched against a database to identify peptides and filtered to achieve a 1% protein false 179 discovery rate. TMT intensities were extracted, filtered, normalized, and summarized into peptide and protein 180 quantification results. A total of 22,005 proteins representing 7,074 protein groups were identified and 7,014 protein 181 groups were quantified. Statistical analysis was performed to determine cutoff for altered proteins and to evaluate 182 associated false discovery rate. In this case the significance threshold was set at p < 0.005 with a minimum of 3 peptides 183 detected. A total of 8 peptides and 34 spectral counts were detected for Gabra2. 184
Generation of CRISPR-engineered mice. Knockin mice (B6-Gabra2 em1Geh / J) were produced with CRISPR/Cas9 using 185 techniques as described (Blednov et al., 2017) . Briefly, a sgRNA targeting Gabra2 at the intron/exon junction near Chr 5 186 at 71,014,638 Mb (GRCm38/mm10 assembly) was identified using the WTSI Genome Editing database (Hodgkins et al., 187 2015 the cytoplasm of B6J one-cell embryos as described Blednov et al., 2017) . Pups resulting from injected 198 embryos were screened for DNA sequence changes in intron 3 of the Gabra2 gene by PCR/DNA sequence analysis. 199
Briefly, a 447 bp amplicon spanning the knockin site was PCR amplified with forward (CAACCAGGAGGGGAAAGACA) and 200 reverse (TTCGAAGCAGCTTGTTTGGC) primers. PCR products were sequenced directly or subcloned into pCR2.1-TOPO 201 (Invitrogen) and sequenced. All mice were genotyped by DNA sequence analysis (Sanger sequencing) using this 202 approach. 203
The male founder (F0) was subsequently crossed to a female B6J mouse to generate F1 progeny. F1 mice were 204 crossed to generate F2 mice. The colony is maintained through heterozygous breeding and all molecular and behavioral 205 phenotyping were performed in generations F2 and higher. 206
Analysis of CRISPR/Cas9 off-target effects. The CRISPOR program (CRISPOR v4.0; crispor.tefor.net) was used to search for 207 off-target sites (Haeussler et al., 2016 ). For precise genome editing, the sgRNA must match a 20 nucleotide target 208 sequence in the genomic DNA (protospacer sequence) that includes a protospacer adjacent motif (PAM) with sequence 209 NGG (where N is any nucleotide). The sgRNA target sequence (TGAATCATAAACTTATATTTAGG) and PAM used to 210 generate CRISPR-engineered mice was predicted to generate 245 off-targets using the CRISPOR tool. However, all 211 predicted off-targets included two (8 predicted off-target sites), three (57 predicted off-target sites), or four (380 212 predicted off-target sites) mismatches in the 12 bp adjacent to the PAM site. Perfect matches are more likely to 213 generate off-target effects compared to mismatches. All off-targets were given an off-target score (cutting frequency 214 determination or CFD score (Doench et al., 2016) ) in the CRISPOR program. We ranked candidates by the CFD score and 215 selected the top 15 predicted off-target sites for confirmation using traditional capillary sequencing (described above). 216
All of these sites contained at least 4 mismatches and were located in intergenic or intronic regions (STable 1). All sites 217 were located in intergenic or intronic regions with high sequence complexity and repetitive sequences. As a result, two 218 of the primer pairs failed to produce a PCR product, even when using B6J genomic DNA. 219
Analysis of global gene expression in CRISPR-engineered Gabra2 mice. Cortex, hippocampus, and striatum were 220 harvested from three male and three female Gabra2 -/and Gabra2 KI/KI mice aged 100 to 130 days-of-age as described 221 above. RNA was extracted using the RNeasy Lipid Tissue kit (Qiagen) and contaminating genomic DNA was removed 222 following treatment with DNAse (Qiagen). RNA quantity was measured using a Nanodrop2000 Spectrophotometer 223 (ThermoScientific) and quality was assessed using the RNA nano chip and Bioanalyzer (Agilent). All samples had RNA 224 integrity values (RIN) over 8. Gene expression was measured using the Clariom D Assay mouse (Thermo Fisher Scientific). 225
Sample preparation and hybridization was performed according to the manufacturers protocol and performed by the 226 UTHSC MRC Institutional Core. Affymetrix Expression Console Software (Thermo Fisher Scientific) was used to annotate 227 and process raw probe cell intensity (CEL) files. The Gene Level-SST-RMA algorithm was used to perform signal space 228 transformation (SST) and guanine cytosine count correction prior to robust multi-array average (RMA) normalization on 229 the batch of 36 samples (3 brain regions x 2 sexes x 3 biological replicates x 2 genotypes). There were no outliers 230 following normalization. The data set was filtered to include only "Main" category probe sets corresponding to 231 annotated coding and non-coding transcripts with a variance > 0.1 across all samples. This reduced the data set from 232 72,688 to 12,699 probe sets. This data set was used for enrichment analysis, comparison of downstream effects of 233 Gabra2 variation in the BXD family of strains, and to investigate possible compensatory changes in other α subunits 234 following reduction of Gabra2. For each analysis, genes with differential expression between Gabra2 KI/KI and Gabra2 -/-235 were detected using Students t-test in R to compare expression of each gene by genotype. Male and female samples of 236 each genotype were pooled for the analysis. 
Results
249
Reduced levels of Gabra2 occur only in the B6J substrain. The B6J strain showed the lowest levels of Gabra2 among 16 250 common and wild-derivative inbred strains, including the closely related C57BL/6ByJ substrain (Fig. 1A) . This difference 251 was robustly detected across expression platforms and was not dependent on sex or brain region. For example, average 252 log2 expression of Gabra2 in the hippocampus was 9.3 for B6J and 11.2 for D2 with over 3.6-fold variation across inbred 253 strains of mice (Affymetrix M430 array, Fig. 1A ). The decrease in Gabra2 mRNA levels was global, and this reduction 254 relative to D2 was also detected in 10 mesocorticolimbic regions (RNA-seq, Fig. 1B ). To evaluate whether reduced levels 255 of Gabra2 were only evident in B6J, we examined expression in a small pedigree of C57BL/6 substrains with defined dates 256 of separation-B6J, B6(Cg) -TyrC-2J/J(B6C2J), C57BL/6EiJ (B6EiJ), C57BL/6JByJ (B6ByJ), C57BL/6NJ (B6NJ), and C57BL/6NCrl 257 (B6NCrl) (Fig. 1C ). Of these substrains, B6EiJ was the most recently separated from B6J in 1976. The albino strain (B6C2J) 258 was maintained as an inbred colony since the discovery of the albino mutation around 1970 (Townsend et al., 1981) but 259 over the past decade has been repeatedly backcrossed to B6J stock and is therefore now listed as a congenic (Cg) strain 260 of B6J rather than as an independent substrain. Expression of Gabra2 in cortex, striatum, and hippocampus was 261 significantly higher (p < 0.05) in B6EiJ, B6ByJ, B6NJ, B6NCrl, and D2 as compared to B6J and B6C2J (Fig. 1D) Fig. 1D-1E , SFig3) and 264 recent crosses between B6J and C3H/HeJ or B6J and CAST/EiJ (Mulligan et al., 2012) . Lower expression in these crosses 265 was always associated with inheritance of the B6J parental allele of Gabra2. F2 intercrosses can also be used to estimate 266 the effect of each allele on expression and mode of inheritance. In F2 crosses in which B6J is a parental strain, the B6J 267 allele was completely recessive (SFig4). Taken together, there is strong evidence that a spontaneous mutation in the 268
Gabra2 gene was fixed in the B6J foundation stock colony at the Jackson Laboratory between 1976 and 1991. This 269 mutation greatly reduces brain expression of Gabra2 mRNA in B6J and all known derivative strains. 270
To evaluate whether the private B6J mutation also leads to a reduction in protein level, we measured GABRA2 271 expression using traditional Western blots and shotgun proteomics methods. We first compared expression between 272 B6J and D2 using an unpublished hippocampal proteome dataset generated using the tandem mass tag (TMT) approach. 273 Significantly (p < 0.005) less Gabra2 normalized peptide counts were detected in B6J (0.77 ± 0.04) relative to D2 (1.23 ± 274 0.07) (Fig. 1G) . To confirm and expand upon this finding, we probed with antibodies specific for Gabra2 in the 275 hippocampus and also detected a marked reduction in protein levels in the B6J strain compared to both the D2 strain 276 and the B6NJ substrain ( Fig. 1H, SFig 1) . 277
Identification of candidate non-coding sequence variants modulating Gabra2 expression. The Gabra2 gene resides in a 278
genomic region that is largely identical by descent among inbred strains, with the exception of the wild derived strains 279 (e.g. CAST/EiJ, PWK/PhJ, and SPRET/EiJ) and contains very few known sequence variants, most of which are located 280 within intronic or intergenic regions. B6J and derivative congenic strains, such as B6C2J, are the lowest expressing 281 individuals from a panel of inbred strains and C57BL/6 substrains (Fig. 1) . Thus, the causal sequence variant must share a 282 common pattern that differentiates B6J from all other inbred strains and substrains. To identify candidate variants near 283 the Gabra2 locus we used existing resources generated by our group (100X coverage of the D2 genome available at 284 http://ucscbrowser.genenetwork.org/ (Wang et al., 2016) ) and the Wellcome Trust Sanger Institute (>30X average 285 coverage of the genomes of 36 inbred mouse strains, including the B6NJ substrain available at 286 http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl). Using these resources, we identified one SNP and 287 two insertion/deletions (indels) that were of high sequence quality. All three were private to B6J compared to B6NJ and 288 D2. We were able to independently validate one SNP and one indel by capillary-based dideoxynucleotide sequencing. 289
Validated candidate polymorphisms were located either ~30 Kb downstream of the Gabra2 gene locus in an intergenic 290 region with high conservation among the mammalian lineage (SNP rs29547790 located on Chr 5 at 70.93 Mb) or in an 291 intron (the third nucleotide from exon 4) adjacent to a splice acceptor site (indel located on Chr 5 at 71.01 Mb) ( Fig. 2A) . 292
To identify the causal variant, we genotyped D2, C57BL/6 substrains, and BXD strains that differed in the level of 293
Gabra2 expression based on inheritance of the presumed wild type allele prior to the late 1970s (D2, B6ByJ, B6NJ, B6EiJ 294 and BXD29) or the mutant allele which was fixed in the B6J substrain between 1976 and 1991 (B6J and BXD40). 295 Importantly, only the genotype at the intronic variant was perfectly associated with Gabra2 expression levels ( Fig. 2A) . 296
Strains with the mutant allele (single base deletion), such as B6J and BXD40, had low expression of Gabra2 compared to 297 the five strains with the wild type allele. The intronic variant was located near a splice acceptor site but the specific 298 impact on splicing is not known. However, striatal RNA-seq data (Bottomly et al., 2011 ) generated for B6J (n = 10) and 299 D2 (n = 11) revealed a higher number of reads mapping both to the intron containing the enigmatic deletion and two 300 downstream introns in the B6J strain (Fig. 2B) which could indicate errors in mRNA processing. Significantly higher 301 intronic expression (probe 4462485; p < 0.001) was also detected among BXD strains (BXD33 through 100) that inherited 302 the B6J allele (6.1 ± 0.22) compared to those that inherited the D2 allele (5.06 ± 0.13) using an exon microarray platform 303 (GeneNetwork data set GN206, UMUTAffy Hippocampus Exon (Feb09) RMA; Fig. 2C ). All Gabra2 exons are expressed at 304 the mRNA level in BXD strains regardless of allele, suggesting that the variant does not produce alternative mRNA 305 isoforms. Instead, all coding exons have higher expression in strains that inherited the D2 (D) allele, and three introns 306 containing or immediately downstream of the variant have higher expression in strains that inherited the B6J (B) allele 307 ( Fig. 2C) . In sum, a non-coding intronic deletion is the sole candidate variant responsible for decreased Gabra2 mRNA 308 and protein expression in B6J. 309
Repair of the candidate non-coding variant is sufficient to restore Gabra2 levels in B6J. To test whether the intronic 310
deletion is sufficient to globally reduce brain mRNA and protein in B6J we used the CRISPR (clustered regularly 311 interspaced short palindromic repeats) and CRISPR associated (Cas9) system to repair the mutation on a pure B6J 312 genetic background (Gabra2 B6J/B6J ; Fig. 3A ). Insertion (knockin; KI) of a single nucleotide was sufficient to fully restore 313
Gabra2 protein (Fig. 3B , SFig 2) and mRNA levels (Fig. 3C ) in brain tissue of B6-Gabra2 em1Geh / J homozygous knockin (KI, 314
Gabra2 KI/KI ) and heterozygous (HET, Gabra2 KI/B6J ) F2 offspring (Fig. 3D) . These results are consistent with the recessive 315 mode of inheritance of the mutant and hypomorphic B6J allele (Gabra2 B6J/B6J ) that is associated with reduced expression 316 due to the presence of the intronic deletion. The use of CRISPR engineering can produce both off-target effects and 317 founders that are mosaic for the introduced mutation (e.g. some cells may have the mutation, some may not, and other 318 cells may have different mutations). However, the expression level of Gabra2 protein and mRNA in the brain tissue of 319 the founder mouse was equivalent to strains without the Gabra2 deletion (e.g. ByJ and NJ; Fig. 3B and 3C) indicating 320 correction in most, if not all, neurons of the founder mouse. In addition, no off-target modifications were detected in 321 the top 15 predicted off-target sites in the F0 mouse and his progeny compared to the B6J reference genome (see 322 methods and STable 1). 323
Intronic Gabra2 deletion is associated with alterations in GABAergic striatal gene expression and signaling. To precisely 324
identify biological processes or pathways altered by variation in Gabra2 levels in the striatum, hippocampus, and cortex, 325 we performed enrichment analysis on genes differentially expressed (p < 0.01; 684 genes) between homozygous 326
Gabra2 KI/KI mice with "normal" Gabra2 levels and "mutant" Gabra2 B6J/B6J mice with low levels of Gabra2. No significantly 327 enriched categories were observed for differentially expressed genes from the cortex or hippocampus. However, a 328 number of enriched categories (FDR adjusted p-value < 0.05) related to GABAergic synaptic signaling were detected in 329 striatum, including ion transmembrane transport, localization to the synapse, GABA receptor activity, retrograde 330 endocannabinoid receptor signaling, dopaminergic synapse, cAMP signaling pathway, and GABAergic synapse (STable 2 331 and STable 3). Mammalian Phenotype Ontology terms related to emotional behavior, cognition, anxiety, sensorimotor 332 gating, fear, and reward were also enriched, albeit at a nominally significant level. These results indicated that 333 alterations in GABAergic signaling, specifically in the striatum, might be a direct downstream consequence of reduced 334
Gabra2 levels. 335
Alterations in GABAergic signaling could result from the loss of Gabra2-containing receptors or changes in the 336 composition of GABA-A receptors to reflect inclusion of other alpha subunits in the absence of Gabra2. To begin to 337 address these issues, we compared the transcript levels of all major GABA-A receptor subunits (α1-6; β1-3, γ1-3, and δ) 338 in multiple brain regions between homozygous Gabra2 KI/KI mice with normal Gabra2 levels and mice harboring the 339 mutant B6J allele (Gabra2 B6J/B6J ). In addition to a large and significant reduction in Gabra2 mRNA, the transcript levels of 340 several major GABA-A receptor alpha subunits (Gabra1, Gabra3, Gabra5) were also significantly reduced in striatum of 341 Gabra2 B6J/B6J mice relative to the Gabra2 KI/KI mice (Fig. 4) . In contrast, the level of Gabra4 was modestly increased in 342
Gabra2 B6J/B6J mice. In striatum, alterations in alpha subunits were accompanied by significant decreases in beta (1 and 2) 343 and gamma (1 and 2) subunits and a significant increase in the delta subunit (B6J allele relative to KI allele; Fig. 4 ). Highly 344 significant alterations in alpha subunits were not observed in the hippocampus or cortex between genotypes, but there 345 was a trend for increased expression of both the α1 subunit in the cortex and the α3 subunit in the hippocampus (B6J 346 allele relative to KI allele). In the cortex there was an associated trend for increased expression of the β1 subunit and 347 decreased expression of the γ1 subunit. In the hippocampus, there was a significant decrease in γ1 subunit levels and a 348 trend for decreased expression of the β1 and γ3 subunits. Taken together, these results suggest that decreased levels of 349
Gabra2 associated with the B6J allele are also associated with profound alterations in the level and composition of 350 GABA-A receptor subunits, especially in the striatum. 351
Discussion
352
Using a combination of genetic, genomic, functional, and bioinformatics approaches we have identified a private 353 and non-coding single nucleotide deletion in the Gabra2 gene in the B6J strain that results in substantial reduction of 354 brain mRNA and protein levels (Fig. 1, Fig. 2 ). Repair of this deletion using CRISPR-Cas9 genome editing fully restored 355
Gabra2 levels (Fig. 3) on the B6J genetic background. The resulting genetically engineered rodent model system 356 (Gabra2 B6J/B6J and Gabra2 KI/KI mice) is thus, a valuable resource for probing the molecular and behavioral consequences of 357 alterations in Gabra2 expression. These results have important implications for any investigators using B6J as their 358 background strain for molecular genetic studies of neurobiology and behavior, in particular those involving study of the 359 GABA system. 360
Unlike previous studies in which function of Gabra2 was probed through complete genetic deletion, the 361 mutation associated with the B6J allele of Gabra2 is hypomorphic and not a complete null. Complete deletion of 362 function represents an extreme case in biological systems and there are often many compensatory changes that can 363 make interpretation of results difficult. Compensation by other α subunits has not been profiled extensively in Gabra2 364 KO mouse lines and some differences in behavior could be due to enhanced expression of other subunits and 365 differences in genetic background as existing Gabra2 KO mice differ in the proportion of B6J and 129/SvEv genetic 366 background. In contrast, our study probed the role of natural variation in the level of Gabra2 in the context of an 367 isogenic B6J background and profiled the expression of all major GABA-A subunits in cortex, striatum, and 368 hippocampus-regions involved in different aspects of mood disorders and addiction. Surprisingly, even in the context 369 of an isogenic B6J background, we detected many alterations in GABAergic signaling at the transcriptional level and 370 observed changes in GABA-A receptor subunit expression between Gabra2 B6J/B6J and Gabra2 KI/KI in all three regions with 371 the most profound alterations detected in the striatum. Regardless of brain region, the major alteration (fold change 372 >2.5) was the loss of Gabra2 subunits. However, the levels of other alpha subunits were also altered ( Fig. 4) , albeit at a 373 much lower level (<1.5 fold). Exceptions include the levels of Gabra5 (1.7 fold decrease relative to Gabra2 KI/KI ) and 374
Gabra3 (2.5 fold decrease relative to Gabra2 KI/KI ) in the striatum. There are no known mutations in Gabra3 or Gabra5 in 375 the B6J background, so the reduction in their levels in striatum must be a direct result of the reduction in Gabra2. Based 376 on the available data, our hypothesis is that there are simply fewer α2 containing GABA-A receptors in B6J derived 377 strains, and possibly fewer GABA-A receptors in some regions. This is supported by the trend towards decreased cortical 378 α2:γ1 subunit levels, decreased hippocampal α2:β1:γ1 and α2:β1:γ3 subunit levels, and decreases in multiple alpha, 379 beta, and gamma subunit levels in the striatum of Gabra2 B6J/B6J relative to Gabra2 KI/KI . The pronounced impact of the B6J 380 mutation on GABA-A receptor subunit expression in the striatum, combined with the involvement of the striatum in 381 anxiety and behavioral sensitization to alcohol and other drugs of abuse, strongly suggests that alterations in the level of 382
Gabra2 in this region drive related behavioral differences between mice with the low-expressing B6J allele and the high-383
expressing wild type allele. Future functional studies exploring behavior and inhibitory neurotransmission across 384 multiple brain regions in B6-Gabra2 em1Geh / J genotypes will test this hypothesis. 385
Overall, the findings of our study have broad implications for both mouse and human research. Despite 386 numerous associations between human GABRA2 variants and addiction-related traits, the mechanisms underlying these 387 associations are unclear. To date, there is no direct link between variants in GABRA2 and alterations in gene expression 388 or function in human brain. However, if functional variants in GABRA2 exist, they are almost certainly non-coding 389 variants that exert functional impact through alteration of splicing, gene regulation, or mRNA stability as opposed to 390 variants resulting in a complete loss of function. This may be similar to the function of the non-coding variant controlling 391 variation in Gabra2 levels in crosses involving B6J and in our B6-Gabra2 em1Geh / J preclinical model system and suggests 392 that non-coding variants in GABRA2 in human populations might be functional and causal. Evaluating and confirming the 393 functional impact of these variants in human populations is extremely difficult due to the complexity of human genetics 394 and environmental factors as well as the limited ability to assay brain gene expression and circuitry. Therefore, 395 preclinical models such as ours are of vital importance for generating new hypotheses, endophenotypes, and underlying 396 molecular mechanisms to test in human populations. This might include the generation of humanized mice in which 397 candidate functional GABRA2 variants are introduced into the Gabra2 corrected B6J genetic background that is 398 permissive for detection of variants that modulate Gabra2 expression. 399
We discovered a functional variant causing reduced Gabra2 expression in B6J, the gold standard reference 400 genome in mouse genetics research and the most widely used inbred strain in biomedical research. It is now critical to 401 re-evaluate gene deletion and other studies in light of the naturally occurring mutation in Gabra2. For example, the 402
Gabra2 locus was recently posited to be a genetic modifier of genetic deletion of Scn1a, a voltage-gated sodium channel 403 gene implicated in a spectrum of seizure-related disorders in humans (Hawkins et al., 2016 ). Hawkins and colleagues 404 observed that the genetic background of Scn1a +/mutations impacted the severity of the epilepsy phenotype such that 405 mutations generated on a B6J background had increased seizures and premature death compared to the same mutation 406 on a 129S6/SvEvTac background, which had a normal phenotype. Our study suggests a specific hypothesis, namely that 407 reduced Gabra2 expression and alterations in GABAergic signaling comprise the causal mechanism underlying 408 enhanced seizure susceptibility induced by Scn1a deletion on the permissive B6J background. Likewise, because the B6J 409 strain is also the most widely used reference strain for biomedical research, several findings in this strain may be 410 confounded by alterations in Gabra2 and other GABA-A subunits. However, as long as investigators are aware of gene 411 variants with a large impact on expression and function, such as the non-coding variant in Gabra2, these naturally 412 occurring mutations can be vital tools for discovery and systems genetics (Li et 
